POM-V
Prescription Required
Companion Animal
Torphadine 10 mg/ml Solution for Injection for Dogs, Cats and Horses
Active ingredient: Butorphanol
Form
Injection
Species
Cats
Dogs
Horses
Manufacturer
Le Vet Beheer B.V.
VMD MA No.
41821/4037
What it's used for
As a premedicant prior to general – anaesthesia: - prior to induction of general anaesthesia. A dose-related reduction in the dose of induction-anaesthetic...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Butorphanol
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Torphadine 10 mg/ml Solution for Injection for Dogs, Cats and Horses — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
As a premedicant prior to general – anaesthesia:
-
prior to induction of general anaesthesia. A dose-related reduction in the dose of
induction-anaesthetic agent (propofol or thiopentone) is also provided.
-
AN: 02201/2024 & 02204/2024
As an anaesthetic:
-
Cat:
As an analgesic for the relief of moderate pain:
-
-
As a sedative:
-
agonists (medetomidine).
As an anaesthetic:
-
suitable for short painful anaesthetic procedures.
Horse:
As an analgesic:
-
gastrointestinal origin.
As a sedative:
-
agonists (detomidine, romifidine).
-
prior to induction of general anaesthesia. A dose-related reduction in the dose of
induction-anaesthetic agent (propofol or thiopentone) is also provided.
-
AN: 02201/2024 & 02204/2024
As an anaesthetic:
-
Cat:
As an analgesic for the relief of moderate pain:
-
-
As a sedative:
-
agonists (medetomidine).
As an anaesthetic:
-
suitable for short painful anaesthetic procedures.
Horse:
As an analgesic:
-
gastrointestinal origin.
As a sedative:
-
agonists (detomidine, romifidine).
Horse: Intravenous use.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Dog:
For analgesia:
Route
Dose
butorphanol
Dose product
IV,IM or
SC
0.20-0.30 mg/kg bw0.02-0.03 ml/kg bw
Comment
IV injection should be slow.
Analgesic effects are seen within 15 minutes of injection.
Administer 15 minutes before terminating anesthesia to provide
analgesia in the recovery phase.
For continuous analgesia repeat dose as required.
For sedation in combination with medetomidine hydrochloride:
Dose
butorphanol
Dose product
Dose
medetomidine hydrochlorideRoute
IM or
IV
0.1 mg/kg bw0.01 ml/kg bw0.01*-0.025**mg/kg bw
Comment
Allow 20 minutes for profound sedation to develop before
commencing the procedure.
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
*Depending on degree of sedation required:
premedicant to barbiturate anaesthesia
**Depending on degree of sedation required
as a premedicant to ketamine anaesthesia
For use as a premedicant/pre-anaesthetic:
- When the veterinary medicinal product is used as the sole agent:
RouteDose butorphanolDose product
IV, IM or
SC
0.1-0.20 mg/kg bw0.01-0.02 ml/kg bw
Comment15 minutes prior to induction
AN: 02201/2024 & 02204/2024
- When the veterinary medicinal product is used together with 0.02 mg/kg
acepromazine:
RouteDose butorphanolDose product
IV or IM 0.10 mg/kg bw*0.01 ml/kg bw*
Comment
Allow at least 20 minutes before the onset of action but the time
between pre-medication and induction is flexible from 20-120 minutes.
Where compatibility is accepted, products containing butorphanol and
acepromazine may be combined and administered in the same
syringe (see section 5.1).
* The dose may be increased to 0.2 mg/kg (equivalent to 0.02 ml/kg) if the animal is
already experiencing pain before the procedure commences or if a higher plane of
analgesia is required during surgery.
For anaesthesia in combination with medetomidine and ketamine:
Dose
butorphanol
Dose product
Dose
medetomidine
Dose
ketamineRouteIM0.10 mg/kg bw0.01 ml/kg bw
0.025mg/kg
bw
5.0mg/kg bw*
Comment
Reversal with atipamezole is not recommended
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
* Ketamine should be administered 15 minutes after the IM administration of the
butorphanol/medetomidine combination.
Cat:
For pre-operative analgesia:
Route
Dose
butorphanol
Dose
product
IM or
SC
0.4 mg/kg bw0.04 ml/kg bw
CommentAdminister 15-30 minutes prior to the administration of IV induction
anaesthetic agents.
Administer 5 minutes before induction with IM induction anaesthetic
agents such as combinations of IM acepromazine/ ketamine or
xylazine/ketamine.
AN: 02201/2024 & 02204/2024
For post-operative analgesia:
Route
Dose
butorphanol
Dose
productSC or IM0.4 mg/kg bw
0.04 ml /kg bw
IV0.1 mg/kg bw
0.01 ml /kg bw
CommentAdminister 15 minutes before recovery
For sedation in combination with medetomidine hydrochloride:
Dose
butorphanol
Dose
product
Dose
medetomidine
hydrochloride
Route
IM or SC0.4 mg/kg bw0.04 ml/kg bw0.05 mg/kg bw
CommentLocal anaesthetic infiltration should be used for wound suturing.
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
For anaesthesia in combination with medetomidine and ketamine:
Dose
butorphanol
Dose
product
Dose
medetomidine
Dose
ketamineRouteIM0.40 mg/kg bw0.04 ml/kg bw0.08 mg/kg bw5.0 mg/kg bw
IV
0.10 mg/kg bw
0.01 ml/kg bw0.04 mg/kg bw
1.25-2.50 mg/kg
bw (depending on
depth of
anaesthesia
required)
CommentWhere compatibility is accepted, products containing medetomidine,
butorphanol and ketamine may be combined and administered in the
same syringe (see section 5.1).
AN: 02201/2024 & 02204/2024
Horse:
For analgesia:
RouteDose butorphanolDose product
IV0.10 mg/kg bw
1 ml/100 kg bw
CommentAnalgesic effects are seen within 15 minutes of injection.
Dose may be repeated as required.
For sedation in combination with detomidine hydrochloride:
Route
Dose of
detomidine
hydrochloride
Dose
butorphanol*
Dose product
IV0.012 mg/kg bw0.025 mg/kg bw0.25 ml/100 kg bw
Comment
Detomidine should be administered up to 5 minutes before the
butorphanol dose.
*Clinical experience has shown that a total dose rate of 5 mg detomidine
hydrochloride and
10 mg butorphanol affords effective, safe sedation in horses above 200 kg body
weight.
For sedation in combination with romifidine:
Route
Dose of
romifidine
Dose
butorphanol
Dose productIV
0.04-0.12 mg/kg
bw
0.02 mg/kg bw0.2 ml/100 kg bwComment
Romifidine should be administered up to 5 minutes before the
butorphanol dose.
Before this veterinary medicinal
syringe as another veterinary medicinal product always refer to the section on 'Major
incompatibilities' (section 5.1).
The maximum number of vial punctures when using needle sizes 21G and 23G
should not exceed 100 and when using a 18G needle, the maximum should not
exceed 40.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Dog:
For analgesia:
Route
Dose
butorphanol
Dose product
IV,IM or
SC
0.20-0.30 mg/kg bw0.02-0.03 ml/kg bw
Comment
IV injection should be slow.
Analgesic effects are seen within 15 minutes of injection.
Administer 15 minutes before terminating anesthesia to provide
analgesia in the recovery phase.
For continuous analgesia repeat dose as required.
For sedation in combination with medetomidine hydrochloride:
Dose
butorphanol
Dose product
Dose
medetomidine hydrochlorideRoute
IM or
IV
0.1 mg/kg bw0.01 ml/kg bw0.01*-0.025**mg/kg bw
Comment
Allow 20 minutes for profound sedation to develop before
commencing the procedure.
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
*Depending on degree of sedation required:
premedicant to barbiturate anaesthesia
**Depending on degree of sedation required
as a premedicant to ketamine anaesthesia
For use as a premedicant/pre-anaesthetic:
- When the veterinary medicinal product is used as the sole agent:
RouteDose butorphanolDose product
IV, IM or
SC
0.1-0.20 mg/kg bw0.01-0.02 ml/kg bw
Comment15 minutes prior to induction
AN: 02201/2024 & 02204/2024
- When the veterinary medicinal product is used together with 0.02 mg/kg
acepromazine:
RouteDose butorphanolDose product
IV or IM 0.10 mg/kg bw*0.01 ml/kg bw*
Comment
Allow at least 20 minutes before the onset of action but the time
between pre-medication and induction is flexible from 20-120 minutes.
Where compatibility is accepted, products containing butorphanol and
acepromazine may be combined and administered in the same
syringe (see section 5.1).
* The dose may be increased to 0.2 mg/kg (equivalent to 0.02 ml/kg) if the animal is
already experiencing pain before the procedure commences or if a higher plane of
analgesia is required during surgery.
For anaesthesia in combination with medetomidine and ketamine:
Dose
butorphanol
Dose product
Dose
medetomidine
Dose
ketamineRouteIM0.10 mg/kg bw0.01 ml/kg bw
0.025mg/kg
bw
5.0mg/kg bw*
Comment
Reversal with atipamezole is not recommended
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
* Ketamine should be administered 15 minutes after the IM administration of the
butorphanol/medetomidine combination.
Cat:
For pre-operative analgesia:
Route
Dose
butorphanol
Dose
product
IM or
SC
0.4 mg/kg bw0.04 ml/kg bw
CommentAdminister 15-30 minutes prior to the administration of IV induction
anaesthetic agents.
Administer 5 minutes before induction with IM induction anaesthetic
agents such as combinations of IM acepromazine/ ketamine or
xylazine/ketamine.
AN: 02201/2024 & 02204/2024
For post-operative analgesia:
Route
Dose
butorphanol
Dose
productSC or IM0.4 mg/kg bw
0.04 ml /kg bw
IV0.1 mg/kg bw
0.01 ml /kg bw
CommentAdminister 15 minutes before recovery
For sedation in combination with medetomidine hydrochloride:
Dose
butorphanol
Dose
product
Dose
medetomidine
hydrochloride
Route
IM or SC0.4 mg/kg bw0.04 ml/kg bw0.05 mg/kg bw
CommentLocal anaesthetic infiltration should be used for wound suturing.
Where compatibility is accepted, products containing medetomidine
and butorphanol may be combined and administered in the same
syringe (see section 5.1).
For anaesthesia in combination with medetomidine and ketamine:
Dose
butorphanol
Dose
product
Dose
medetomidine
Dose
ketamineRouteIM0.40 mg/kg bw0.04 ml/kg bw0.08 mg/kg bw5.0 mg/kg bw
IV
0.10 mg/kg bw
0.01 ml/kg bw0.04 mg/kg bw
1.25-2.50 mg/kg
bw (depending on
depth of
anaesthesia
required)
CommentWhere compatibility is accepted, products containing medetomidine,
butorphanol and ketamine may be combined and administered in the
same syringe (see section 5.1).
AN: 02201/2024 & 02204/2024
Horse:
For analgesia:
RouteDose butorphanolDose product
IV0.10 mg/kg bw
1 ml/100 kg bw
CommentAnalgesic effects are seen within 15 minutes of injection.
Dose may be repeated as required.
For sedation in combination with detomidine hydrochloride:
Route
Dose of
detomidine
hydrochloride
Dose
butorphanol*
Dose product
IV0.012 mg/kg bw0.025 mg/kg bw0.25 ml/100 kg bw
Comment
Detomidine should be administered up to 5 minutes before the
butorphanol dose.
*Clinical experience has shown that a total dose rate of 5 mg detomidine
hydrochloride and
10 mg butorphanol affords effective, safe sedation in horses above 200 kg body
weight.
For sedation in combination with romifidine:
Route
Dose of
romifidine
Dose
butorphanol
Dose productIV
0.04-0.12 mg/kg
bw
0.02 mg/kg bw0.2 ml/100 kg bwComment
Romifidine should be administered up to 5 minutes before the
butorphanol dose.
Before this veterinary medicinal
syringe as another veterinary medicinal product always refer to the section on 'Major
incompatibilities' (section 5.1).
The maximum number of vial punctures when using needle sizes 21G and 23G
should not exceed 100 and when using a 18G needle, the maximum should not
exceed 40.
All target species:
Do not use in animals with severe dysfunction of the liver or kidneys.
Do not use in animals with cerebral injury or organic brain lesions.
Do not use in animals with obstructive respiratory disease, heart dysfunction or
spastic conditions.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Horse:
Butorphanol/detomidine hydrochloride combination:
Do not use in horses with a pre-existing cardiac dysrhythmia or bradycardia.
Do not use in cases of colic associated with impaction as the combination will cause
a reduction in gastrointestinal motility.
Do not use in horses with emphysema due to a possible depressive effect on the
respiratory system.
Do not use in pregnant mares.
Butorphanol/romifidine combination:
Do not use during the last month of pregnancy.
Do not use in animals with severe dysfunction of the liver or kidneys.
Do not use in animals with cerebral injury or organic brain lesions.
Do not use in animals with obstructive respiratory disease, heart dysfunction or
spastic conditions.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Horse:
Butorphanol/detomidine hydrochloride combination:
Do not use in horses with a pre-existing cardiac dysrhythmia or bradycardia.
Do not use in cases of colic associated with impaction as the combination will cause
a reduction in gastrointestinal motility.
Do not use in horses with emphysema due to a possible depressive effect on the
respiratory system.
Do not use in pregnant mares.
Butorphanol/romifidine combination:
Do not use during the last month of pregnancy.
Horses:
Very common
(>1 animal / 10 animals
treated):
Sedation
a
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain
b
Ataxia
c
, Increased motor activity
d
, Shivering
Restlessness, Excitatory locomotor effects (e.g.
pacing)
e
Digestive tract hypomotility
f
Undetermined frequency
(cannot be estimated from the
available data):
Cardiac depression
g
Respiratory depression
g
a
Mild sedation may occur in approximately 15% of horses following administration of
butorphanol as a sole agent.
b
On intramuscular injection.
c
Mild ataxia may persist for 3 to 10 minutes but ataxia can also last for 1 – 2 hours in
some cases. Mild to severe ataxia may be encountered in combination with
detomidine, but horses are unlikely to collapse. Normal precautions should be
observed to prevent injury (see section 3.5).
d
Can last for 1-2 hours in some cases.
e
After a bolus i.v. injection at the maximum label dose (0.1 mg/kg body weight) in
clinically normal horses.
f
In normal horses, although there is no decrease in gastrointestinal transit time.
These effects are dose-related, and generally minor and transient.
g
When used in combination with alpha2-adrenoceptor agonists, cardiopulmonary
system depression may be fatal in rare cases.
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Ataxia
a
Anorexia
a
Diarrhoea
a
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Sedation
Respiratory depression
b
(e.g. decreased
respiratory rate)
Cardiac depression
b
(e.g. bradycardia
c
, low blood
pressure
d
)
Undetermined frequency
(cannot be estimated from the
available data):
Injection site pain
e
Digestive tract hypomotility
AN: 02201/2024 & 02204/2024
a
Transient.
b
The degree of depression is dose-dependent. If respiratory depression occurs,
naloxone may be used as an antidote. Moderate to marked cardiopulmonary
depression may occur if butorphanol is given rapidly by intravenous injection.
c
When using butorphanol as a pre-anaesthetic, the use of an anticholinergic such as
atropine, will protect the heart against possible narcotic-induced bradycardia.
d
A decrease in diastolic pressure (see section 3.5).
e
On intramuscular injection.
Cats:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Respiratory depression
a
Mydriasis
Excitation
Undetermined frequency
(cannot be estimated from the
available data):
Injection site pain
b
Sedation, Disorientation
Anxiety
Dysphoria
a
Naloxone may be used as an antidote.
b
On intramuscular injection.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Very common
(>1 animal / 10 animals
treated):
Sedation
a
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain
b
Ataxia
c
, Increased motor activity
d
, Shivering
Restlessness, Excitatory locomotor effects (e.g.
pacing)
e
Digestive tract hypomotility
f
Undetermined frequency
(cannot be estimated from the
available data):
Cardiac depression
g
Respiratory depression
g
a
Mild sedation may occur in approximately 15% of horses following administration of
butorphanol as a sole agent.
b
On intramuscular injection.
c
Mild ataxia may persist for 3 to 10 minutes but ataxia can also last for 1 – 2 hours in
some cases. Mild to severe ataxia may be encountered in combination with
detomidine, but horses are unlikely to collapse. Normal precautions should be
observed to prevent injury (see section 3.5).
d
Can last for 1-2 hours in some cases.
e
After a bolus i.v. injection at the maximum label dose (0.1 mg/kg body weight) in
clinically normal horses.
f
In normal horses, although there is no decrease in gastrointestinal transit time.
These effects are dose-related, and generally minor and transient.
g
When used in combination with alpha2-adrenoceptor agonists, cardiopulmonary
system depression may be fatal in rare cases.
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Ataxia
a
Anorexia
a
Diarrhoea
a
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Sedation
Respiratory depression
b
(e.g. decreased
respiratory rate)
Cardiac depression
b
(e.g. bradycardia
c
, low blood
pressure
d
)
Undetermined frequency
(cannot be estimated from the
available data):
Injection site pain
e
Digestive tract hypomotility
AN: 02201/2024 & 02204/2024
a
Transient.
b
The degree of depression is dose-dependent. If respiratory depression occurs,
naloxone may be used as an antidote. Moderate to marked cardiopulmonary
depression may occur if butorphanol is given rapidly by intravenous injection.
c
When using butorphanol as a pre-anaesthetic, the use of an anticholinergic such as
atropine, will protect the heart against possible narcotic-induced bradycardia.
d
A decrease in diastolic pressure (see section 3.5).
e
On intramuscular injection.
Cats:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Respiratory depression
a
Mydriasis
Excitation
Undetermined frequency
(cannot be estimated from the
available data):
Injection site pain
b
Sedation, Disorientation
Anxiety
Dysphoria
a
Naloxone may be used as an antidote.
b
On intramuscular injection.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Butorphanol is intended for use where short duration analgesia (horse, dog) or short
to medium duration analgesia (cat) is required (see section 4.2). In cases where
longer duration analgesia is likely to be required, an alternative therapeutic agent
should be used.
AN: 02201/2024 & 02204/2024
Marked sedation does not occur when butorphanol is used as a sole agent in cats.
In cats, individual response to butorphanol may be variable. In the absence of an
adequate analgesic response, an alternative analgesic agent should be used.
In cats increasing of the dose will not increase intensity or duration of desired effects.
Special precautions for safe use in the target species:
All target species:
Due to its antitussive properties, butorphanol may lead to an accumulation of mucous
in the respiratory tract. Therefore, in animals with respiratory diseases associated
with increased mucous production, butorphanol should only be used according to a
benefit-risk assessment by the responsible veterinary surgeon.
Prior to use of the veterinary medicinal product in combination with α2-
adrenoreceptor agonists routine cardiac auscultation should be performed and the
concurrent use of anticholinergic drugs, e.g. atropine should be considered.
The combination of butorphanol and an α2-adrenoceptor agonists should be used
with caution in animals with mild to moderate dysfunction of the liver or kidney.
Take care when administering butorphanol to animals concurrently treated with other
central nervous depressants (see section 3.8).
The safety of the veterinary medicinal product in puppies, kitten and foals has not
been established and therefore in these animals the veterinary medicinal product
should only be used according to a benefit-risk assessment by the responsible
veterinary surgeon.
Dog:
When administering as an intravenous injection, do not inject rapidly as a bolus.
In dogs with MDR1 mutation reduce dose by 25-50%
Cat:
Use of either insulin syringes or 1 ml graduated syringes is recommended.
Horse:
The use of the veterinary medicinal product at the recommended dose may lead to
transient ataxia and/or excitement. Therefore, to prevent injuries, in the patient and
people when treating horses, the location for the treatment should be chosen
carefully.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Butorphanol has opioid activity.
The most frequent adverse effects of butorphanol in humans are drowsiness,
sweating, nausea, dizziness and vertigo and these may occur following unintended
self-injection. Care should be taken to avoid accidental injection/self-injection.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician. Do not drive. An opioid antagonist (e.g.
naloxone) may be used as an antidote.
Wash any splashes from skin and eyes immediately.
AN: 02201/2024 & 02204/2024
Special precautions for the protection of the environment:
Not applicable.
to medium duration analgesia (cat) is required (see section 4.2). In cases where
longer duration analgesia is likely to be required, an alternative therapeutic agent
should be used.
AN: 02201/2024 & 02204/2024
Marked sedation does not occur when butorphanol is used as a sole agent in cats.
In cats, individual response to butorphanol may be variable. In the absence of an
adequate analgesic response, an alternative analgesic agent should be used.
In cats increasing of the dose will not increase intensity or duration of desired effects.
Special precautions for safe use in the target species:
All target species:
Due to its antitussive properties, butorphanol may lead to an accumulation of mucous
in the respiratory tract. Therefore, in animals with respiratory diseases associated
with increased mucous production, butorphanol should only be used according to a
benefit-risk assessment by the responsible veterinary surgeon.
Prior to use of the veterinary medicinal product in combination with α2-
adrenoreceptor agonists routine cardiac auscultation should be performed and the
concurrent use of anticholinergic drugs, e.g. atropine should be considered.
The combination of butorphanol and an α2-adrenoceptor agonists should be used
with caution in animals with mild to moderate dysfunction of the liver or kidney.
Take care when administering butorphanol to animals concurrently treated with other
central nervous depressants (see section 3.8).
The safety of the veterinary medicinal product in puppies, kitten and foals has not
been established and therefore in these animals the veterinary medicinal product
should only be used according to a benefit-risk assessment by the responsible
veterinary surgeon.
Dog:
When administering as an intravenous injection, do not inject rapidly as a bolus.
In dogs with MDR1 mutation reduce dose by 25-50%
Cat:
Use of either insulin syringes or 1 ml graduated syringes is recommended.
Horse:
The use of the veterinary medicinal product at the recommended dose may lead to
transient ataxia and/or excitement. Therefore, to prevent injuries, in the patient and
people when treating horses, the location for the treatment should be chosen
carefully.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Butorphanol has opioid activity.
The most frequent adverse effects of butorphanol in humans are drowsiness,
sweating, nausea, dizziness and vertigo and these may occur following unintended
self-injection. Care should be taken to avoid accidental injection/self-injection.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician. Do not drive. An opioid antagonist (e.g.
naloxone) may be used as an antidote.
Wash any splashes from skin and eyes immediately.
AN: 02201/2024 & 02204/2024
Special precautions for the protection of the environment:
Not applicable.
When butorphanol is used in combination with certain α2-adrenoceptor agonists
(romifidine or detomidine in horses, medetomidine in dogs and cats) synergistic
effects occur requiring a butorphanol dose reduction (see section 3.5 and 3.9).
Butorphanol is antitussive and should not be used in combination with an expectorant
as it may lead to an accumulation of mucous in the airways.
Butorphanol has antagonist properties at the opiate mu (μ) receptor which may
remove the analgesic effect of pure opioid mu (μ) agonists (e.g.
morphine/oxymorphine) in animals that have already received these agents.
The concomitant use of other central nervous depressants would be expected to
potentiate the effects of butorphanol and such drugs should be used with caution.
AN: 02201/2024 & 02204/2024
A reduced butorphanol dose should be used when administering these agents
concurrently.
(romifidine or detomidine in horses, medetomidine in dogs and cats) synergistic
effects occur requiring a butorphanol dose reduction (see section 3.5 and 3.9).
Butorphanol is antitussive and should not be used in combination with an expectorant
as it may lead to an accumulation of mucous in the airways.
Butorphanol has antagonist properties at the opiate mu (μ) receptor which may
remove the analgesic effect of pure opioid mu (μ) agonists (e.g.
morphine/oxymorphine) in animals that have already received these agents.
The concomitant use of other central nervous depressants would be expected to
potentiate the effects of butorphanol and such drugs should be used with caution.
AN: 02201/2024 & 02204/2024
A reduced butorphanol dose should be used when administering these agents
concurrently.
This veterinary medicinal product does not require any special storage conditions.
Meat and offal: zero days.
Not authorised for use in mares producing milk for human consumption.
Not authorised for use in mares producing milk for human consumption.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Butorphanol
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VV.M.D. n.v.
injection
Cats
Dogs
Horses
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VV.M.D. n.v.
injection
Cats
Dogs
Horses
Butador 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Horses
Butador 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Horses
ButorVet 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VC&H Generics Ltd
injection
Cats
Dogs
Horses
ButorVet 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VC&H Generics Ltd
injection
Cats
Dogs
Horses
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in painkiller
Related Medications
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
injection
Rx
Cats
Dogs
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
injection
Rx
Cats
Dogs
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.